#New Zealand #Auckland #Aroa Biosurgery #Myriad Matrix #Limb Salvage

New Findings on Myriad™ Technology in Limb Salvage Surgeries

A striking announcement from Aroa Biosurgery, a company based in New Zealand, has unveiled significant clinical data that highlights the effectiveness of its AROA ECM™ technology in challenging lower limb salvage surgeries. This study was conducted from May 2022 to April 2023 and specifically analyzed cases involving 130 complex lower limb defects across 120 patients. What stands out is that 95% of the participants had at least one risk factor linked to the potential for lower limb amputation, with 55% presenting three or more such predictive indicators.

Lower limb amputation carries severe repercussions for patients, both physically and psychologically. Research indicates that the five-year mortality rate for individuals who undergo this procedure can reach a staggering 50%. Given this backdrop, the findings of Aroa's recent study are particularly important. Published in the esteemed Plastic and Reconstructive Surgery – Global Open journal, the groundbreaking study is the largest of its kind aimed at inpatient reconstruction involving a dermal matrix for lower extremities. Dubbed "Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A Prospective Study," this is the inaugural publication resulting from Aroa's ongoing Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR).

Crucially, the study demonstrated that the Myriad Matrix™ and Myriad Morcells™ achieved successful tissue coverage and fill within just 30 days, following a single application of the product. Remarkably, no infections or complications were reported during this period. This reinforces the effectiveness of Myriad products in managing complex lower extremity reconstructions.

Moreover, the economic implications of the study are equally compelling. Aroa discovered an estimated cost difference of up to 195% when compared to other available dermal matrices on the market for inpatient lower extremity reconstruction. This finding not only emphasizes the clinical efficacy of the Myriad technology but also its substantial cost benefits, appealing to both medical practitioners and health care systems alike.

Brian Ward, the founder and CEO of Aroa Biosurgery, expressed his enthusiasm regarding these findings, stating, “We are very pleased to see the first clinical evidence emerge from our large prospective MASTRR study. The evidence from this study further validates both the efficacy of, and potential cost benefits associated with Myriad’s use in lower limb reconstruction procedures.” With a total addressable market estimated at $225 million for lower limb procedures alone, the opportunities for Aroa are substantial.

Dr. John Lawlor, an accomplished Foot and Ankle Surgeon leading the study, echoed this sentiment. “I've been using AROA's Myriad products for several years now and have seen the difference they can make in my patient population,” he noted. “It’s very encouraging to see this large study published, quantifying the significant positive impact on patients and the overall cost benefits of using Myriad to manage such a complex patient group. I am excited to share our positive outcome data with my colleagues in the surgical field.”

The revelations from this study mark a significant step forward in the field of lower limb surgeries, providing hope to patients and doctors alike. As the healthcare community continues to seek effective solutions for limb salvage surgeries, Aroa Biosurgery's Myriad technology emerges as a promising option that not only enhances patient outcomes but does so with considerable cost-efficiency.